Jefferies & Co. is reiterating its Buy rating and $17 price target on shares of Optimer Pharm. OPTR.
In a note to clients, Jefferies writes, "For lead drug fidaxomicin, FDA's AdComm panel and PDUFA date are set for April 5 and May 30, respectively. While the Street sentiment is optimistic, we view potential upside likely to continue particularly from its current inexpensive valuation (estimated current EV of <$400M).
The Street is optimistic about the upcoming AdComm panel (4/5/11), but
somewhat cautious about a commercial launch; however, at its inexpensive
current valuation, we expect potential incremental upside likely to continue.
OPTR has achieved several key milestones for fidaxomicin in recent months - (1) priority review by the FDA; (2) publication of first Ph3 in prestigious journal The New England Journal of Medicine (NEJM); and (3) ex-U.S. partnership with Astellas. Yet, the Street's expectations for OPTR are modest at best (reflected in current valuation); thus, there lies an opportunity. We view our fidaxomicin peak WW annual sales potential of ~$250M as easily achievable (vs. current Vancocin annual sales runrate of ~$260M in the U.S. alone)."
Shares of OPTR lost 19 cents yesterday to close at $12.35, a loss of 1.5%.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in